Limitless Research Inc.
1 clinical trials · Sponsor
◉ Watch Limitless Research Inc.
| Record | Firm | Date |
|---|---|---|
| The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care (NCT05298410) | Limitless Research Inc. | 2022-03-17 |
Track Limitless Research Inc. automatically
Every clearance here is in the API, with alerts when new ones post.